Joint Replacement with an infection?

Find out if you qualify to participate in a clinical research study that may help.

Qualified participants may receive:
  • Evaluations, exams, lab work
  • Investigational product or placebo
  • Compensation for time and travel
  • Study-related treatment at no cost

Study Snapshot

Purpose: This study is to learn whether phage, viruses designed to attack bacteria, are a safe and effective treatment for infections after joint replacements when given with antibiotics and debridement.

Infections after joint replacement can lead to serious complications.

Joint infection can show up any time after surgery including more than a year later. People with joint replacement infections can have serious complications requiring treatment with antibiotics and additional surgeries.

The infection in the joint can spread and become very serious. If left untreated, a neglected infection can lead to amputation.

This study is to learn whether phage can effectively treat joint-replacement infections.

What to expect as a part of this trial:

If you meet the three basic qualifications listed below, you’ll be directed to a clinic in your area to finish the screening process. If you are a match and want to participate, the clinic will walk you through the steps for enrollment and the informed consent process.

A patient choosing to participate in this study will be asked to undergo screening tests (such as blood tests or x-rays) or procedures (such as joint fluid samples) to determine eligibility.

Interested in joining this trial? Just 3 simple questions to get started:

1 Are you between
18 and 85 years old?

2 Have an infected hip or knee replacement?

3 Had no previous surgical treatment or only one previous debridement for your joint infection?

Note: Other conditions not specified above may result in exclusion from the study.

If you answer yes to all three questions, you may qualify to participate in a research study that may help.

To get started, contact us!

This site is intended for U.S. residents.

See our privacy policy

Adaptive Phage Therapeutics